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Abstract: PURPOSE Transforming growth factor (TGF)-฀ is expressed at high levels by glioma cells
and contributes to the malignant phenotype of glioblastoma. However, its therapeutic targeting remains
challenging. Here, we examined an alternative therapeutic approach of TGF฀ inhibition using two novel
phosphorothioate-locked nucleic acid (LNA)-modified antisense oligonucleotide gapmers, ISTH1047 and
ISTH0047, which specifically target TGF฀ and TGF฀. EXPERIMENTAL DESIGN We characterized the
effects of ISTH1047 and ISTH0047 on TGF฀ expression, downstream signaling and growth of human LN-
308, LN-229, and ZH-161 cells as well as murine SMA-560 glioma cells . Furthermore, we assessed their
target inhibition and effects on survival in orthotopic xenogeneic and syngeneic rodent glioma models .
RESULTS Both antisense oligonucleotides specifically silenced their corresponding target and abrogated
SMAD2 phosphorylation in several glioma cell lines. Moreover, inhibition of TGF฀ or TGF฀ expression
by ISTH1047 or ISTH0047 reduced the migration and invasiveness of LN-308 and SMA-560 glioma
cells. Systemic antisense oligonucleotide administration to glioma-bearing mice suppressed or mRNA
expression as well as the expression of the downstream target in orthotopic gliomas. Glioma-bearing mice
had significantly prolonged survival upon systemic treatment with ISTH1047 or ISTH0047, which was
associated with a reduction of intratumoral SMAD2 phosphorylation and, in a fully immunocompetent
model, with increased immune cell infiltration. CONCLUSIONS Targeting TGF฀ expression with the
novel LNA antisense oligonucleotides ISTH1047 or ISTH0047 results in strong antiglioma activity and ,
which may represent a promising approach to be examined in human patients with glioma.
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Statement of translational relevance  28 
Transforming growth factor (TGF)-β has been attributed an important role in glioblastoma 29 
progression and may be a key player in tumor invasion, angiogenesis and 30 
immunosuppression. Targeting the TGF-β pathway has been regarded a promising 31 
therapeutic strategic but the approaches used to date have failed due to insufficient 32 
inhibition of the TGF-β pathway or dose-limiting toxicity. In this study, we directly inhibited 33 
TGF-β1 or TGF-β2 expression with novel second-generation antisense oligonucleotides 34 
(ASO). We demonstrate that ASO-mediated TGF-β inhibition reduces the invasive 35 
potential of glioma cells, while increasing the number of tumor-infiltrating immune cells. 36 
These novel TGF-β-targeting ASO reach the tumor upon systemic administration and 37 
prolong survival of both immunocompetent and immune-deficient mice bearing orthotopic 38 
gliomas. Therefore, this study represents a major improvement in TGF-β-targeted 39 










Abstract  47 
 48 
Purpose: Transforming growth factor (TGF)-β is expressed at high levels by glioma cells 49 
and contributes to the malignant phenotype of glioblastoma. However, its therapeutic 50 
targeting remains challenging. Here, we examined an alternative therapeutic approach of 51 
TGF-β inhibition using two novel phosphorothioate-locked nucleic acid (LNA)-modified 52 
antisense oligonucleotide gapmers, ISTH1047 and ISTH0047, which specifically target 53 
TGF-β1 and TGF-β2. 54 
Experimental design: We characterized the effects of ISTH1047 and ISTH0047 on TGF-55 
β1/2 expression, downstream signaling and growth of human LN-308, LN-229 and ZH-161 56 
cells as well as murine SMA-560 glioma cells in vitro. Furthermore, we assessed their 57 
target inhibition and effects on survival in orthotopic xenogeneic and syngeneic rodent 58 
glioma models in vivo. 59 
Results: Both antisense oligonucleotides specifically silenced their corresponding target 60 
and abrogated SMAD2 phosphorylation in several glioma cell lines. Moreover, inhibition 61 
of TGF-β1 or TGF-β2 expression by ISTH1047 or ISTH0047 reduced migration and 62 
invasiveness of LN-308 and SMA-560 glioma cells. Systemic ASO administration to 63 
glioma-bearing mice suppressed TGF-β1 or TGF-β2 mRNA expression as well as the 64 
expression of the down-stream target PAI-1 in orthotopic gliomas. Glioma-bearing mice 65 
had significantly prolonged survival upon systemic treatment with ISTH1047 or 66 
ISTH0047, which was associated with a reduction of intratumoral SMAD2 67 





Conclusions: Targeting TGF-β expression with the novel LNA antisense 70 
oligonucleotides ISTH1047 or ISTH0047 results in strong anti-glioma activity in vitro and 71 
in vivo which may represent a promising approach to be examined in human glioma 72 
























Glioblastoma is the most lethal primary tumor of the central nervous system (CNS) in 94 
adults. The current standard of care for newly diagnosed glioblastoma includes surgical 95 
resection followed by radiotherapy and chemotherapy with the alkylating agent, 96 
temozolomide (TMZ). However, the median survival of glioblastoma patients is still limited 97 
to approximately 16 months with a 5-year survival rate of less than 10% within clinical 98 
trials (1). A key mediator of the malignant phenotype of glioma cells is transforming growth 99 
factor (TGF)-β. It has pleiotropic functions and exists as three different mature ligands, 100 
TGF-β1, TGF-β2 and TGF-β3 (2). All are involved in the phosphorylation of SMAD2 and 101 
SMAD3 proteins which are responsible for transcriptional regulation of genes involved in 102 
tumor infiltration and epithelial to mesenchymal transition (EMT), but also 103 
immunosuppression and angiogenesis (3,4). Elevated levels of TGF-β as well as the 104 
activation of the TGF-β/SMAD cascade correlates with high tumor grade and in some 105 
cases with poor prognosis in glioblastoma patients (5,6). Gliomas generate an 106 
immunosuppressive tumor microenvironment through the secretion of a variety of 107 
cytokines, including TGF-β that can impede anti-tumor immune responses (3). 108 
Furthermore, TGF-β signaling enhances the invasiveness and migratory ability of glioma 109 
cells and maintains a drug-resistant stem cell phenotype (7,8). Consequently, targeting 110 
the TGF-β pathway represents an attractive therapeutic approach. In this regard, various 111 
strategies have been explored in vitro and in vivo including gene transfer of TGF-β 112 
scavengers such as decorin (9), furin protease inhibitors which interfere with the 113 
processing of TGF-β (10) or indirect TGF-β signaling targeting through integrin inhibition 114 




such as SD-208 (12), galunisertib (13) or LY2109761 (14) and the pan TGF-β antibody, 116 
1D11 (15). Despite promising pre-clinical data, these agents failed to show a clear clinical 117 
benefit in glioblastoma patients (16,17).  Therefore, the clinical development of most of 118 
these drugs has been stopped because of lack of activity, most likely due to insufficient 119 
target inhibition or dose-limiting toxicity (16). 120 
Antisense oligonucleotides (ASO) are single-stranded, biochemically-modified 121 
deoxyribonucleotide molecules that are 15–25 nucleotides in length. They are designed 122 
as complementary sequences to a target gene’s mRNA thereby specifically inhibiting 123 
gene expression (18). The concept of ASO-mediated gene silencing has emerged as a 124 
potentially powerful alternative or concomitant treatment to conventional cancer therapy.  125 
There is a plethora of genes related to cancer progression or therapeutic resistance which 126 
cannot be targeted efficiently with antibodies or small molecules but possibly with ASO. 127 
Because of their targeted mode of action, ASO may be less toxic than many conventional 128 
anti-tumor therapeutics (19). One of the most clinically advanced TGF-β-targeting 129 
approaches involved the locoregional application of AP12009 (trabedersen), a first 130 
generation ASO with a sequence complementary to human TGF-β2 mRNA, in a 131 
randomized phase II trial in patients with recurrent anaplastic glioma or glioblastoma. 132 
Even though AP12009 was not inferior to standard chemotherapy, no convincing efficacy 133 
signal was seen (20). 134 
Given the insufficient results obtained with the TGF-β-targeting strategies explored so far, 135 
we aimed at assessing TGF-β signaling inhibition in glioma models using two novel 136 
second-generation phosphorothioate-locked nucleic acid (LNA)-modified ASO. The 137 




binding affinity and higher tissue concentrations (21,22). Here, we assessed the anti-139 
glioma activity of two novel LNA-modified ASO molecules which specifically target TGF-140 
























Materials and methods 162 
Reagents and cell lines 163 
The human malignant glioma cell lines LN-308 and LN-229 were kindly provided by Dr. 164 
N. de Tribolet (Lausanne, Switzerland). The mouse glioma cell line SMA-560 was derived 165 
from a spontaneous astrocytoma in a VM/Dk mouse (23) and provided by Dr. D. Bigner 166 
(Durham, NC). The glioma cell lines were maintained in Dulbecco’s modified Eagle’s 167 
medium supplemented with 10% fetal calf serum (Biochrom, Minneapolis, MN) and 2 168 
mmol/L L-glutamine (Gibco Life Technologies, Paisley, UK). The glioma-initiating cell 169 
(GIC) line ZH-161 was established after informed consent and approval of the Swiss 170 
ethical committees and characterized in detail (24). ZH-161 cells were grown in 171 
Neurobasal medium supplemented with 2 µl/ml B-27 without vitamin A, 2 mM L-glutamine 172 
(Gibco Life Technologies), fibroblast growth factor (FGF)-2 and epidermal growth factor 173 
(EGF) (20 ng/mL each, Peprotech, Rocky Hill, PA). All cells were grown in a humidified 174 
37ºC incubator with 5% CO2. ISTH1047, ISTH0047 and C3_ISTH0047 (scrambled 175 
control) antisense oligonucleotides were designed and provided by ISARNA Therapeutics 176 
GmbH (Munich, Germany). ISTH1047, targeting TGF-β1 (sequence 177 
TCGATGCGCTTCCG), and ISTH0047, targeting TGF-β2 (sequence 178 
CAAAGTATTTGGTCTCC), represent 14-mer and 17-mer, full locked nucleic acid (LNA)-179 
modified antisense oligonucleotide gapmers (Suppl. Fig. 1). The specificity of each ASO 180 
was confirmed via the NCBI BLAST  software (https://blast.ncbi.nlm.nih.gov/Blast.cgi) to 181 
align oligonucleotides to human and murine TGF-β1 or TGF-β2 sequences (Suppl. Fig. 2). 182 
Digoxigenin (DIG)-labelled ISTH1047 was also provided by ISARNA Therapeutics 183 




MN). SD-208 was provided by Scios (Fremont, CA) and galunisertib (LY2157299) by Eli 185 
Lilly Co (Indianapolis, IN). 186 
Real-time quantitative PCR 187 
Total RNA was isolated with the NucleoSpin System (Macherey-Nagel, Düren, Germany) 188 
and cDNA was retro-transcribed using Invitrogen Superscript II reverse transcriptase 189 
(ThermoFisher Scientific, Waltham, MA). For real-time quantitative PCR, cDNA 190 
amplification was quantified using SYBR Green chemistry on the 7300 Real time PCR 191 
System (Applied Biosystems, Zug, Switzerland). The conditions for the PCR reactions 192 
were: 40 cycles, 95 °C/15 sec, 60 °C/1 min. Human and mouse HPRT1 transcript levels 193 
were used as a reference for relative quantification of mRNA expression levels via the 194 ∆CTt method (25). The following specific primers were used: human HPRT1 fwd: 5’-TGA 195 
GGA TTT GGA AAG GGT GT-3’; human HPRT1 rev: 5’-GAG CAC ACA GAG GGC TAC 196 
AA-3’; human TGF-β1 fwd: 5'-GCC CTG GAC ACC AAC TAT TG-3'; human TGF-β1 rev: 197 
5'-CGT GTC CAG GCT CCA AAT G-3’; human TGF-β2 fwd: 5'-AAG CTT ACA CTG TCC 198 
CTG CTG C-3'; human TGF-β2 rev: 5'-TGT GGA GGT GCC ATC AAT ACC T-3’; human 199 
TGF-β3 fwd: 5′-ATG ACC CAC GTC CCC TAT CA-3′, human TGF-β3 rev: 5′-CAG ACA 200 
GCC AGT TCG TTG TG-3′; mouse HPRT1 fwd: 5’-TTG CTG ACC TGC TGG ATT AC-201 
3’; mouse HPRT1 rev: 5’-TTT ATG TCC CCC GTT GAC TG-3’; mouse TGF-β1 fwd: 5’-202 
CTC CCG TGG CTT CTA GTG C-3’; mouse TGF-β1 rev: 5’-GCC TTA GTT TGG ACA 203 
GGA TCT G-3’; mouse TGF-β2 fwd: 5'-TCG ACA TGG CTT CTA GTG C-3’; mouse TGF-204 
β2 rev: 5'-CCC TGG TAC TGT TGT AGA TGG A-3’; mouse TGF-β3 fwd: 5′-205 
AGCATCCACTGTCCATGTCA-3′, mouse TGF-β3 rev: 5′-TTCTTCCTCTGACTGCCCTG-206 




TTA CC-3’, mouse plasminogen activator inhibitor (PAI)-1 rev: 5'-GAC ACG CCA TAG 208 
GGA GAG AAG-3’. For expression analysis of human targets in the oligonucleotide-209 
treated xenograft mouse model, the following human-specific primers, which do not 210 
recognize the mouse TGF-β1, TGF-β2 or TGF-β3 isoforms, were used: TGF-β1 fwd: 5′- 211 
CAATTCCTGGCGATACCTCAG-3′; TGF-β1 rev: 5′-GCACAACTCCGGTGACATCAA-3′; 212 
TGF-β2 fwd: 5′-CAGCACACTCGATATGGACCA-3′; TGF-β2 rev: 5′-213 
CCTCGGGCTCAGGATAGTCT-3′; TGF-β3 fwd: 5′-AACGGTGATGACCCACGTC-3′, 214 
TGF-β3 rev: 5′-CCGACTCGGTGTTTTCCTGG-3′; PAI1 fwd: 5′-215 




Whole protein lysates were generated by lysing the cells with lysis buffer P (26). 220 
Denatured whole protein lysates and concentrated supernatants (30 μg/lane) were 221 
separated on 10-15% acrylamide gels. After transfer to nitrocellulose (Biorad, Hercules, 222 
CA), blots were blocked in 5% milk-TBST and incubated overnight at 4°C with primary 223 
antibodies specific for: total SMAD2 (clone 86F7, Cell Signaling, Boston, MA) 224 
phosphorylated SMAD2 (pSMAD2) (clone 138D4, Cell Signaling), total SMAD3 (Cell 225 
Signaling), phosphorylated SMAD3 (pSMAD3) (clone C25A9, Cell Signaling), total AKT 226 
(Cell Signaling), phosphorylated AKT (pAKT) (Cell Signaling) and β-actin (clone sc-1616, 227 
Santa Cruz Biotechnologies, Santa Cruz, CA). The membranes were then washed in 228 
TBST and incubated for 1 h at room temperature with horseradish peroxidase (HRP)-229 




Santa Cruz Biotechnologies). Protein bands were visualized by enhanced 231 
chemoluminescence (Pierce/Thermo Fisher, Madison, WI).  232 
 233 
Animal studies 234 
All procedures were performed in accordance with the Cantonal Veterinary Office Zurich 235 
and Federal Food Safety and Veterinary Office. For the xenograft models, Crl: CD1 Foxn1 236 
nude mice were purchased from Charles River Laboratories (Wilmington, MA). For the 237 
syngeneic studies, VM/Dk mice were bred in house. Mice of 6-10 weeks of age were used 238 
in all experiments. Mice were anaesthetized using an intraperitoneal 3 component 239 
injection consisting of fentanyl, midazolam and medetomidin (26). For intracranial tumor 240 
cell implantation, the mice were fixed under a stereotactic device (Stoelting, Wood Dale, 241 
IL) and a burr hole was drilled in the skull 2 mm lateral and 1 mm posterior to the bregma. 242 
A Hamilton syringe needle was introduced to a depth of 3 mm. LN-308, LN-229 or ZH-243 
161 human glioma cells (105) or SMA-560 murine glioma cells (5x103) in a volume of 2 µl 244 
PBS were injected into the right striatum of Crl: CD1 Foxn1 nude or VM/Dk mice, 245 
respectively. C3_ISTH0047 (20 mg/kg), ISTH1047 (10 mg/kg) or ISTH0047 (20 mg/kg) 246 
were injected subcutaneously for five consecutive days for studies that aimed at 247 
assessing target inhibition. Forty-eight hours after the last injection, all mice were PBS-248 
perfused and organs were harvested for further analyses. For survival studies, C3_ ISTH 249 
0047 (20 mg/kg), ISTH1047 (10 mg/kg) or ISTH0047 (20 mg/kg) were injected 250 
subcutaneously for five consecutive days and then twice weekly. Mice were monitored 251 
daily for neurological symptoms according to Cantonal Veterinary Office Zurich guidelines 252 




grade 1 - reduced activity, slight imbalance, balance and coordination impairments; grade 254 
2 – decreased to no activity, 15% weight loss compared with peak weight measured on 255 
tumor inoculation day, slight paralysis of left legs and moderate signs of pain (26). 256 
Treatment was started at day 5 after tumor cell inoculation for VM/Dk mice and at day 25 257 
(LN-308) or day 10 (LN-229, ZH-161) after tumor cell injection for Crl: CD1 Foxn1 nude 258 
animals. For the assessment of oligonucleotide delivery to the brain, digoxigenin (DIG)-259 
labelled ISTH1047 (10 mg/kg) was subcutaneously injected for two consecutive days and 260 
the mice were PBS-perfused 48 h after the last injection. For liver enzyme analyses, blood 261 
was collected from LN-308-bearing mice on the day the first animal became symptomatic 262 
and sent for aspartate transaminase (ASAT) and alanine transaminase (ALAT) 263 
quantification at the Laboratory for Veterinary Medicine (University of Zurich, 264 
Switzerland). 265 
 266 
Statistical analysis 267 
Data were derived from experiments performed at least twice in triplicates with similar 268 
results. Quantitative data are presented as mean ± standard deviation (SD). Statistical 269 
significance was assessed using one-way ANOVA using Bonferroni correction as a post-270 
hoc test. All statistical analyses were performed using Prism 5 (GraphPad Software, La 271 
Jolla, CA) at p<0.05 or p<0.01. 272 
 273 





Results  276 
ISTH1047 and ISTH0047 decrease TGF-β1/2 expression and abrogate TGF-β 277 
signaling in glioma cells in vitro 278 
Based on the chosen sequence, ISTH1047 and ISTH0047 were designed as antisense 279 
oligonucleotides specifically inhibiting TGF-β1 or TGF-β2 (Suppl Fig. 1,2). First, we 280 
examined the biological effects of both oligonucleotides in human LN-308 and mouse 281 
SMA-560 glioma cells in vitro. ISTH1047 down-regulated TGF-β1 protein levels up to 96 282 
h post-transfection in both cell lines, whereas ISTH0047 reduced TGF-β2 protein levels 283 
for up to 96 h in LN-308 cells and 72 h in SMA-560 cells (Fig. 1A,B). Increasing 284 
concentrations of both oligonucleotides reduced the expression of their corresponding 285 
target TGF-β ligand at mRNA level, reaching the highest inhibition efficiency at 50 nM or 286 
more in both cell lines (Suppl Fig. 3A,B). Moreover, TGF-β1 or TGF-β2 mRNA levels were 287 
significantly reduced up to 72 h post-transfection in human LN-308, LN-229 and ZH-161 288 
glioma cells as well as the murine glioma cell line SMA-560. TGF-β3 mRNA levels were 289 
not significantly affected after ASO transfection in LN-308 or SMA-560 cells, but 290 
ISTH0047 exposure increased TGF-β3 levels in LN-229 cells and reduced TGF-β3 mRNA 291 
levels in ZH-161 cells (Fig. 1C). We observed a reduction of intracellular SMAD2 292 
phosphorylation with increasing concentrations of ISTH1047 or ISTH0047 in LN-308 and 293 
SMA-560 cells. ISTH1047 diminished pSMAD2 starting at a concentration of 3.13 nM and 294 
ISTH0047 at 12.5 nM in LN-308 cells (Suppl Fig. 3C). In SMA-560 cells, ISTH1047 295 
abrogated SMAD2 phosphorylation at 50 nM, while ISTH0047 exerted strongest effects 296 
at 100 nM (Suppl Fig. 3D). Total SMAD2 levels were not altered upon ISTH1047 or 297 




levels occurred at 48 h after transfection (Fig. 1D). Similarly, pSMAD3 levels were 299 
reduced in both LN-308 and SMA-560 cells. To assess the effect of TGF-β1 or TGF-β2 300 
inhibition on alternative TGF-β signaling pathways, we examined the phosphorylation 301 
levels of AKT 48 h after ASO exposure. pAKT was reduced following exposure to 302 
ISTH1047 or ISTH0047 only in LN-308 cells (Fig. 1E). In line with these findings, exposure 303 
to ISTH1047 or ISTH0047 reduced pSMAD2 and pSMAD3 expression in LN-229 cells 304 
and the GIC line ZH-161. No consistent effect of ASO-mediated TGF-β  inhibition on 305 
pAKT levels was observed in these cells (Fig. 1F). 306 
 307 
Oligonucleotide-driven TGF-β inhibition impairs glioma cell migration and invasion 308 
We went on to examine the biological effects of ISTH1047 and ISTH0047 on the viability 309 
and clonogenicity of glioma cells. A concentration of 50 nM of either oligonucleotide alone 310 
had no impact on cell viability (Suppl. Fig. 4A,B). Moreover, in clonogenic survival assays, 311 
transfection with either oligonucleotide had no effect in LN-308 cells although ISTH1047 312 
reduced colony formation of SMA-560 cells (Suppl. Fig. 4C,D). Migration and invasion 313 
into the surrounding tissue can be induced by TGF-β and are among the hallmarks of 314 
glioblastoma. Exposure to ISTH1047 reduced migration of LN-308 and SMA-560 cells in 315 
Boyden chamber assays. A similar inhibition of glioma cell migration was observed with 316 
ISTH0047. Conversely, addition of exogenous TGF-β1/2 resulted in increased glioma cell 317 
migration (Fig. 2A,B; Suppl. Fig. 5). To assess whether the two oligonucleotides impair 318 
invasiveness of glioma cells, we performed spheroid invasion assays into a three-319 
dimensional collagen I gel. Spheroid invasion was significantly reduced following TGF-320 




exogenous TGF-β1 stimulation increased invasiveness at 96 h (Fig. 2C; Suppl. Fig. 6A). 322 
In SMA-560 cells, ISTH1047 transfection blocked spheroid formation in agar. Targeting 323 
TGF-β2 using ISTH0047 led to a significant reduction in spheroid invasion, whereas 324 
stimulation with exogenous TGF-β2 increased the invasion of SMA-560 cells (Fig. 2D; 325 
Suppl. Fig. 6B).  326 
 327 
TGFβ1/2 inhibition in murine glioma models in vivo 328 
Because of the strong anti-TGF-β activity of the two ASO molecules observed in vitro, we 329 
aimed at exploring target down-regulation in vivo using the xenogeneic LN-308 as well as 330 
the syngeneic SMA-560 model. To this end, we determined whether systemically 331 
administered ISTH1047 or ISTH0047 reach the tumor site and inhibit TGF-β1 or TGF-β2 332 
expression in experimental gliomas. DIG-labelled ISTH1047 was detected specifically in 333 
the tumor region upon systemic administration in mice bearing LN-308- or SMA-560-334 
derived gliomas (Fig. 3A-E). Moreover, systemic administration of ISTH1047 or ISTH0047 335 
to mice with intracranially growing gliomas resulted in a significant down-regulation of 336 
TGF-β1 or TGF-β2 mRNA expression levels, respectively, in the tumor-bearing 337 
hemisphere without significantly altering TGF-β3 levels (Fig. 3F). To examine whether the 338 
observed target down-regulation had an effect on TGF-β-dependent downstream 339 
signaling, we assessed the expression of PAI1, a classical TGF-β response gene (27). 340 
Indeed, PAI1 mRNA levels were significantly down-regulated in gliomas derived from LN-341 
308 or SMA-560 cells following systemic treatment with ISTH1047 or ISTH0047 (Fig. 3G). 342 
Expression levels of all assessed targets were up-regulated in the tumor-bearing 343 




in the SMA-560 model.TGF-β2 levels were also reduced after ISTH0047 treatment in the 345 
normal hemisphere in both glioma models (Fig. 3F,G). 346 
After confirmation of ASO delivery and target inhibition in experimental gliomas, we 347 
assessed effects on survival. Systemic treatment with either ASO prolonged survival of 348 
mice with orthotopically growing xenogeneic LN-308- or syngeneic SMA-560-derived 349 
gliomas (Fig. 4A,G). Tumor volumes were reduced in mice receiving ISTH1047 or 350 
ISTH0047 treatment in both models (Fig. 4B,H). In LN-229-bearing mice, although only 351 
ISTH0047 exerted a significant survival benefit, neither treatment reduced the tumor 352 
volume at an early time point of analysis (Fig. 4C,D; Suppl. Fig.7). On the contrary, in the 353 
ZH-161 model, we observed a significantly reduced tumor burden in mice treated with 354 
ISTH0047 that exhibited a non-significant trend for better survival compared to control-355 
treated mice (Fig. 4E,F). Furthermore, treatment with ISTH1047 or ISTH0047 reduced 356 
tumoral SMAD2 phosphorylation in LN-308-, LN-229- and SMA-560-bearing mice (Fig. 357 
5). The number of invasive glioma satellites was also decreased in gliomas of mice 358 
treated with TGF-β-targeting ASO (Suppl. Fig. 8).  359 
For a detailed evaluation of host cell infiltration in the tumor, we assessed the frequencies 360 
of different immune cell populations after ISTH1047 or ISTH0047 treatment in the 361 
syngeneic, immunocompetent SMA-560 glioma model. We observed a significant 362 
increase in the CD45+ leukocyte population in ISTH0047-treated mice, which correlated 363 
with an increased infiltration by CD3+ T cells (Fig. 6A,B). Although CD45+/CD3+ cells 364 
exhibited an increase by trend only in ISTH1047-treated mice, the cytotoxic CD8+ T cell 365 
population was significantly enriched in the tumors of mice treated with either ISTH1047 366 




more frequent in the tumor upon ASO treatment (Fig. 6D,E). In terms of blood vessel 368 
density, ISTH0047 reduced the number of CD31+ endothelial cells (Suppl. Fig. 9). 369 
Finally, treatment with either oligonucleotide alone was well tolerated without significant 370 
weight loss. Blood analyses of mice treated with ISTH1047 demonstrated increased 371 
aspartate transaminase (ASAT) and alanine transaminase (ALAT) levels, without any 372 

















Discussion  387 
TGF-β signaling represents a central hub orchestrating various biological functions that 388 
are involved in the malignant phenotype of glioblastoma. TGF-β1 and TGF-β2 are 389 
significantly upregulated compared to normal brain tissue, and the expression of TGF-β1 390 
correlates with the expression of the target gene PAI1 (6). Therefore, a ligand-based 391 
approach to directly inhibit TGF-β1 or TGF-β2 with ASO represents an attractive 392 
therapeutic strategy. The promising but inconclusive results of a trial assessing the local 393 
administration of a first generation ASO targeting human TGF-β2 mRNA (20) led to the 394 
development of two second generation LNA-modified ASO, ISTH1047 and ISTH0047 395 
targeting TGF-β1 and TGF-β2, respectively (Suppl. Fig. 1) that can be administered 396 
systemically. ISTH1047 and ISTH0047 are second-generation ASO that benefit from the 397 
addition of LNA modifications, which increase their RNA binding affinity and confer 398 
enhanced nuclease resistance versus first-generation molecules (28). Here, we 399 
characterized the anti-glioma activity of these novel ASO in human and mouse glioma 400 
models in vitro and in vivo. 401 
TGF-β1 or TGF-β2 levels were significantly reduced in various human and mouse glioma 402 
cells upon exposure to either ASO at low concentrations (Fig. 1A-C; Suppl Fig. 3A,B), 403 
indicating that both molecules result in strong target inhibition. In contrast, AP12009 404 
achieved a significant TGF-β2 reduction only in the µM range (29). Since a biologically 405 
meaningful TGF-β inhibition should lead to a reduction of canonical SMAD-dependent 406 
signaling, we initially examined this pathway in several glioma cell lines. Both ASO 407 
reduced SMAD2 phosphorylation more potently than TGF-βRI kinase inhibition by SD-408 




signaling against adenosine tri-phosphate (ATP)-competitive inhibitors in vitro. In line with 410 
our findings, another approach targeting TGF-β ligands using adenoviral transfer of 411 
soluble TGFβRI and II, resulted in an almost complete reduction of pSMAD2 levels in 412 
glioma cells (30). Indirect approaches against the TGF-β/SMAD2 signaling axis, e.g., via 413 
integrin inhibition have also proven to inhibit glioma progression in preclinical models 414 
(11,31). Iintegrin αvβ8 is upregulated in high grade gliomas and plays a crucial role in 415 
TGF-β1 activation and subsequent SMAD2 signaling. αvβ8 inhibition decreased both 416 
TGF-β1/2 bioavailability inducing almost complete SMAD2 dephosphorylation in LN-308 417 
and LN-229 glioma cells (11). In the current study we show that blocking either TGF-β1 418 
or TGF-β2 expression using ASO approaches, results in a similarly strong reduction of 419 
pSMAD2 levels, suggesting that direct inhibition of a single isoform is sufficient to 420 
abrogate TGF-β/SMAD2 signaling (32,33). Although the exact mechanism for this 421 
remains elusive, we conclude that depleting a single TGF-β isoform may impair auto-422 
feedback loops resulting in strong reduction of pSMAD2 levels, despite the presence of 423 
other isoforms (26,34,35). While similar suppression was detected at the level of another 424 
canonical target, pSMAD3, less activity was seen when exploring pAKT as a 425 
representative non-canonical target of TGF-β, yet, non-canonical signaling in response 426 
to TGF-β is less prominent in our models (Fig. 1E,F). We have recently revealed an 427 
unexpected role for TGF-β3 in the regulation of downstream TGF-β signaling despite high 428 
expression of the other two isoforms in glioblastoma (26). Here, blocking TGF-β1 or TGF-429 
β2 expression influenced TGF-β3 expression only in LN-229 glioma cells (Fig. 1C). This 430 
was also the cell line that exhibited the least potent pSMAD2 reduction after exposure to 431 




compensate for the loss of other isoforms to regulate TGF-β signaling (26). We therefore 433 
hypothesize that the effects of TGF-β isoform-specific inhibition on canonical and non-434 
canonical pathways may be cell-dependent and do not solely rely on the basal expression 435 
of either TGF-β1 or TGF-β2 alone, but also on the potential availability of counter-436 
regulatory pathways.   437 
Exposure of glioma cells to ISTH1047 or ISTH0047 did not affect cell viability (Suppl. Fig. 438 
4), although SMA-560 glioma cells transfected with the TGF-β1-specfic ASO displayed 439 
reduced clonogenic survival, also resulting in lack of spheroid formation for assessment 440 
of invasive potential in vitro (Suppl. Fig. 4D). Ashley et al. (1998) also reported growth-441 
suppressive properties of TGF-β1 inhibition in SMA-560 cells and the induction of 442 
apoptosis, indicating a potential survival dependency of these cells specifically related to 443 
TGF-β1 (35). Reduced migration and invasion of glioma cells upon TGF-β/SMAD singling 444 
blockade has been widely shown (12,14,36). Correlating with the greater pSMAD2 down-445 
regulation after ASO-mediated TGF-β1 or TGF-β2 inhibition (Fig. 1D; Suppl Fig. 3C,D), 446 
these agents also exhibited more pronounced inhibitory effects on the migratory and 447 
invasive potential of glioma cells compared to TGF-βRI kinase inhibition (Fig. 2). The high 448 
binding affinity of LNA-modified ASO to cell surface proteins, such as heparin, can 449 
potentiate their cellular uptake via absorptive endocytosis and consequent target 450 
inhibition (37,38), and combined with the irreversible nature of ASO-mediated target 451 
silencing (39), may explain the superiority of these agents over small molecule ATP-452 
competitive TGF-βR kinase inhibitors (12,40) observed here.  453 
Since drug delivery to gliomas is one of the limiting factors of current novel therapeutic 454 




generation ASO reach the tumor site after systemic treatment in orthotopic murine glioma 456 
models in vivo. Indeed, systemic subcutaneous administration of DIG-labelled ISTH1047 457 
resulted in a strong oligonucleotide accumulation in the tumors with minimal deposition in 458 
the normal contralateral hemisphere (Fig. 3E). Even though in vivo oligonucleotide uptake 459 
pathways are currently poorly understood, LNA modifications are known to improve the 460 
pharmacokinetic properties of ASO, facilitating prolonged tissue half-life and more 461 
efficient cellular uptake compared to AP12009 or other first generation ASO (18). The 462 
only other approach to directly inhibit TGF-β ligand activity represents the intravenous 463 
administration of the pan-TGF-β neutralizing antibody, 1D11 that also appears to 464 
selectively accumulate in the tumor (15). Systemic treatment of glioma-bearing mice with 465 
either of the two ASO molecules resulted in a ligand-specific down-regulation and 466 
reduction of the SMAD-dependent target gene PAI1 in the tumor-bearing hemisphere 467 
(Fig. 3F,G). Given that TGF-β1 and TGF-β2  expression strongly correlate with PAI1 468 
expression in The Cancer Genome Atlas (TCGA) analyses (6), this profound reduction in 469 
TGF-β and PAI1 levels demonstrates that isoform-specific targeting of TGF-β is feasible 470 
and interferes with TGF-β signaling in the tumor following systemic administration. TGF-471 
β1/2 levels were up-regulated in the tumor compared to normal brain in both glioma models 472 
(Fig. 3F) supporting the notion that TGF-β is highly expressed in glioblastoma (5,6). 473 
However, we did not detect any increase in tumoral TGF-β2 compared to normal brain 474 
tissue in SMA-560-bearing mice. The inherent low TGF-β2 expression levels of SMA-560 475 
gliomas have been described before (13), which may not allow for the discrimination of 476 
such changes at the mRNA level between tumoral and normal tissue. TGF-β2 levels in 477 




the specificity and efficacy of these ASO in the glioma setting (Fig. 3F). Reduced TGF-β1 479 
or TGF-β2 levels resulted in a significant reduction of tumor invasiveness in vivo (Suppl. 480 
Fig. 8), and are in line with our in vitro observations of reduced invasive potential (Fig. 481 
2C,D), enhancing the importance of the TGF-β/SMAD pathway as a major mediator of 482 
glioma cell invasion (12,42,43).  483 
Based on these promising data, we determined the anti-glioma activity of both novel 484 
antisense molecules in vivo. ISTH1047 or ISTH0047 treatment significantly reduced 485 
tumor volumes and ultimately prolonged the survival of LN-308 or SMA-560 glioma-486 
bearing mice (Fig. 4A,B,G,H). Consistent with the TGF-β and PAI1 mRNA inhibition data, 487 
pSMAD2 levels were significantly reduced by ISTH1047 or ISTH0047 in both models (Fig. 488 
5A,B,E,F). A recent study with the TGF-βRI antagonist, galunisertib, as monotherapy 489 
showed a marginal survival benefit in the SMA-560 model, while it did not significantly 490 
affect tumor size (13). Moreover, the 1D11 pan-TGF-β-neutralizing antibody resulted in 491 
an almost complete tumor remission when administered daily in immunocompetent mice 492 
bearing subcutaneous gliomas but, the opposite effect was noted when it was given to 493 
immunodeficient glioma-bearing mice, additionally, 1D11 failed to show a therapeutic 494 
effect in an orthotopic glioma model (15). Our ASO-mediated approach utilized a twice 495 
weekly dosage regime after the initial 5-day ASO treatment and led to a striking decrease 496 
of pSMAD2 levels and significant tumor size reduction in the xenogeneic LN-308-bearing 497 
and the syngeneic SMA-560-bearing glioma models. In LN-229-bearing mice, a 498 
significant survival benefit was only observed after ISTH0047 treatment without any 499 
reduction in tumor burden which, however, was assessed at a very early point in time 500 




invasive phenotype that could only be mitigated by ISTH0047-mediated TGF-β2 inhibition 502 
and not by ISTH1047 (Suppl. Fig. 8). Moreover, pSMAD2 expression was almost 503 
eliminated after ISTH0047 treatment suggesting that TGF-β2 inhibition has a potent effect 504 
on the TGF-β pathway in this model (Fig. 5C,D). Therefore, it may be that the survival 505 
benefit observed with ISTH0047 in this model is mainly due to the potent reduction of 506 
tumor infiltration and invasion (42), further supporting the cell-dependent effects of TGF-507 
β isoform inhibition noted in our in vitro studies. We did not observe a significant survival 508 
benefit upon ASO treatment in the GIC model in vivo. However, TGF-β2 inhibition 509 
significantly reduced tumor volume and had the better survival outcome compared to 510 
TGF-β1 inhibition (Fig. 4E,F). In line with this finding, TGF-β2 is known to be an essential 511 
regulator of the self-renewing and tumor propagating capacity of patient-derived GIC (44). 512 
Therefore, a more intensive ISTH0047 treating regime has the potential to exert more 513 
prominent survival benefit in GIC tumor mouse models. 514 
Since TGF-β is a multifunctional cytokine with major immunosuppressive properties, we 515 
assessed the host cell responses to ASO-mediated TGF-β1 or TGF-β2 inhibition in the 516 
syngeneic, immunocompetent SMA-560 glioma model. We noted enhanced immune cell 517 
infiltration in the tumor after ASO treatment. More specifically, the cytotoxic CD45+ CD8+ 518 
T-cell population was significantly increased after either ISTH1047 or ISTH0047 519 
treatment (Fig. 6C). The enhanced tumor infiltration with cytotoxic T cells suggests that 520 
TGF-β depletion allows for an activation of the adaptive anti-tumor immune response. 521 
Interestingly, pSMAD2 depletion correlates with the increased tumoral cytotoxic T cell 522 
infiltration supporting the notion that targeting TGF-β signaling in tumors can restore 523 




reduced number of CD31+ endothelial cells, suggesting that TGF-β2  inhibition may reduce 525 
the number of aberrant tumor blood vessels and thereby facilitate tumor vasculature 526 
normalization (13). Blood vessel normalization is a process associated with a better 527 
trafficking of immune cells in the tumoral bed, which may facilitate cytotoxic T cell 528 
infiltration (46). Overall, these data indicate a potential pro-immunogenic effect of ASO-529 
mediated TGF-β1/2  inhibition that might assist in the elimination of glioma cells, while 530 
reducing their invasive and migratory abilities.  531 
Except for ALAT levels marginally beyond the normal range upon treatment with 532 
ISTH1047, no relevant toxicity was observed in the in vivo survival experiments (Suppl. 533 
Fig. 10). However, when the two ASO molecules were administered as a combinatorial 534 
treatment in the syngeneic SMA-560 glioma model, the mice exhibited severe systemic 535 
toxicity and therefore this treatment arm was not selected for further investigations. For 536 
reasons currently undetermined, LNA-modified ASO have been linked with an increased 537 
risk of acute kidney injury in pre-clinical studies when compared to other second-538 
generation ASO variants (47). However, in vivo pre-clinical toxicology studies tend to 539 
over-predict the renal effects of ASO, as these agents do not appear to exert significant 540 
nephrotoxicity when tested in humans (48). Therefore, even though informative, any 541 
toxicology studies performed in murine glioma models with ISTH1047 or ISTH0047 do 542 
not necessarily predict the situation in glioblastoma patients. Altogether, these data show 543 
that ASO-mediated TGF-β ligand targeting represents an alternative, convenient and 544 
efficient way to block the TGF-β/SMAD pathway resulting in a significant survival benefit 545 





The present dataset strongly suggests that TGF-β retains an important role in 548 
glioblastoma progression and that an efficient targeting approach can potentially improve 549 
clinical outcome. We show strong therapeutic activity of two novel second-generation 550 
TGF-β-specific ASO in two independent glioma models which may now allow for clinical 551 
evaluation of their therapeutic potential in human patients. Given the immune-modulatory 552 
activities of the two ASO molecules, a potential combination of ISTH1047 or ISTH0047 553 
with immune checkpoint inhibitors that are currently explored in clinical neuro-oncology 554 
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Figure legends 570 
 571 
Figure 1. ISTH1047 and ISTH0047 interfere with TGF-β signaling. A,B. LN-308 (A) or 572 
SMA-560 (B) glioma cells were exposed to ISTH1047 or ISTH0047 at 50 nM for 24 h and 573 
TGF-β1/2 protein levels in the cell culture supernatant were determined by ELISA at 48, 574 
72 or 96 h post transfection. C. LN-308, LN-229, ZH-161 or SMA-560 glioma cells were 575 
exposed to ISTH1047 or ISTH0047 at 50 nM for 24 h and TGF-β1/2/3 mRNA levels were 576 
assessed by RT-PCR 48 h post transfection. D,E. LN-308 or SMA-560 glioma cells were 577 
exposed to ISTH1047 or ISTH0047 at 50 nM for 24 h. pSMAD2 (D), pSMAD3, total 578 
SMAD3, pAKT and total AKT (E) levels were assessed by immunoblot at 48 h post 579 
transfection. F. LN-229 or ZH-161 glioma cells were exposed to ISTH1047 or ISTH0047 580 
at 50 nM for 24 h. pSMAD2, total SMAD2, pSMAD3, total SMAD3, pAKT and total AKT 581 
levels were assessed by immunoblot at 48 h post transfection. C3_ISTH0047 at 50 nM 582 
was used as scrambled sequence oligonucleotide control (Ctrl). Exogenous TGF-β1/2 (5 583 
ng/ml) was used to induce pSMAD2 in ZH-161. The TGF-β receptor I kinase inhibitor SD-584 
208 (1 µM) was used as an additional control for TGF-β pathway inhibition. Results are 585 
expressed as means and SD (n=3), statistical analysis was performed with one-way 586 
ANOVA and Bonferroni post-hoc testing (*p < 0.05, ** p < 0.01). 587 
 588 
Figure 2. TGF-β inhibition by ISTH1047 or ISTH0047 reduces glioma cell migration 589 
and invasion. A,B. LN-308 (A) or SMA-560 (B) glioma cells were transfected with 590 
ISTH1047, ISTH0047, control oligonucleotide (Ctrl) or exposed to galunisertib, SD-208 or 591 
recombinant TGF-β1/2 at the indicated concentrations for 72 h and then examined in 592 




membrane. C,D. LN-308 (C) or SMA-560 (D) glioma cells transfected with 50 nM 594 
ISTH1047 or ISTH0047, exposed to 1 µM SD-208, 5 ng/ml TGF-β1 or 5 ng/ml TGF-β2 for 595 
24 h were allowed to form spheroids in agar and seeded in collagen-I. Invasion was 596 
assessed by quantifying the area of invaded cells into the collagen over 96 h. Results are 597 
expressed as means and SD (n=3), statistical analysis was performed with one-way 598 
ANOVA and Bonferroni post-hoc testing (*p < 0.05). 599 
 600 
Figure 3. ASO are detected at the tumor site upon systemic administration and 601 
inhibit TGF-β1 or TGF-β2 expression in orthotopically growing gliomas in vivo. LN-602 
308 (105) or SMA-560 (5x103) glioma cells were injected stereotactically into the right 603 
hemisphere of Crl: CD1 Foxn1 or VM/Dk mice, respectively. A-E. Twenty-five or five days 604 
after tumor inoculation for Crl: CD1 Foxn1 or VM/Dk mice, respectively, systemic 605 
treatment with DIG-ISTH1047 (10 mg/kg) was initiated for 5 consecutive days. Two days 606 
following the last injection, brains from LN-308 (A) or SMA-560 (B) glioma-bearing mice 607 
were collected and histologically assessed for DIG expression in the tumor region using 608 
an anti-mouse DIG antibody. Representative images of DIG fluorescence staining in LN-609 
308 (A) or SMA-560 (B) tumors are shown (DIG, green; nuclei staining with DAPI, blue). 610 
Contralateral normal brain hemisphere was used as additional control (C). Mouse IgG 611 
was used as a negative control (D). Mean fluorescence intensity was quantified using the 612 
Bitplane Imaris software (E). Results are expressed as means and SD (n=3), statistical 613 
analysis was performed with one-way ANOVA and Bonferroni post-hoc testing (*p < 0.05, 614 
** p < 0.01). F, G. Twenty-five or five days after tumor inoculation for Crl: CD1 Foxn1 or 615 




ISTH1047 (10 mg/kg) or ISTH0047 (20 mg/kg) was initiated for 5 consecutive days. Two 617 
days following the last injection, tumor- and non-tumor-bearing (normal) hemispheres 618 
from LN-308 or SMA-560 glioma-bearing mice were collected and assessed for TGF-β1, 619 
TGF-β2, TGF-β3 or PAI1 mRNA expression using RT-qPCR. Human-specific TGF-β1, 620 
TGF-β2, TGF-β3 or PAI1 primer sequences were used to assess target gene expression 621 
in LN-308-derived tumors. Results are expressed as means and SD (n=4), statistical 622 
analysis was performed with one-way ANOVA and Bonferroni post-hoc testing (p < 0.05; 623 
* = control vs treatment in tumor tissue; + = control vs treatment in normal tissue; # = 624 
normal tissue vs. tumor tissue). 625 
 626 
Figure 4. Systemic treatment of glioma-bearing mice with ISTH1047 or ISTH0047 627 
inhibits tumor growth and prolongs survival. A-H. LN-308 (105), LN-229 (105), ZH-628 
161 (105) or SMA-560 (5x103) glioma cells were injected stereotactically into the right 629 
hemisphere of Crl: CD1 Foxn1 or VM/Dk mice, respectively. Twenty-five (LN-308), ten 630 
(LN-229, ZH-161) or five days (SMA-560) after tumor inoculation, systemic treatment with 631 
C3_ISTH0047 (Ctrl) (20 mg/kg), ISTH1047 (10 mg/kg) or ISTH0047 (20 mg/kg) was 632 
initiated for 5 consecutive days. Agents were administered twice weekly thereafter. Mice 633 
were sacrificed when they developed grade 2 neurological symptoms. Survival curves for 634 
LN-308 (A), LN-229 (C), ZH-161 (E) and SMA-560 (G) were analyzed for differences via 635 
log-rank (Martel-Cox) test at *p < 0.05 and **p < 0.01. Brains from three pre-randomized 636 
LN-308 (B), LN-229 (D), ZH-161 (F) or SMA-560 (H) glioma-bearing mice per group were 637 
subjected to for histological analyses when the first mouse developed clinical symptoms. 638 




(B,D,F,H) are expressed as means and SD (n=3), statistical analysis was performed with 640 
one-way ANOVA and Bonferroni post-hoc testing (*p < 0.05). 641 
 642 
Figure 5. ISTH1047 or ISTH0047 treatment reduces tumoral SMAD2 643 
phosphorylation. A-F. LN-308 (105), LN-229 (105) or SMA-560 (5x103) glioma cells were 644 
injected stereotactically into the right hemisphere of Crl: CD1 Foxn1 or VM/Dk mice, 645 
respectively. Twenty-five (LN-308), ten (LN-229) or five days (SMA-560) after tumor 646 
inoculation, systemic treatment with C3_ISTH0047 (Ctrl) (20 mg/kg), ISTH1047 (10 647 
mg/kg) or ISTH0047 (20 mg/kg) was initiated for 5 consecutive days and then 648 
administered twice weekly. Brains from LN-308 (A,B), LN-229 (C,D) or SMA-560 (E,F) 649 
glioma-bearing mice were extracted for histological analyses from three pre-randomized 650 
animals per group when the first mouse developed clinical symptoms to assess pSMAD2 651 
levels. Representative images of pSMAD2 stainings of LN-308 (A), LN-229 (C) or SMA-652 
560-derived (E) tumors are shown (pSMAD2, green; nuclei staining with DAPI, blue). 653 
Mean fluorescence intensity (B,D,F) was quantified using the Bitplane Imaris software. 654 
Results (B,D,F) are expressed as means and SD (n=2-3), statistical analysis was 655 
performed with one-way ANOVA and Bonferroni post-hoc testing (*p < 0.05).  656 
 657 
Figure 6. Modulation of tumor immune cell infiltration in ISTH1047- or ISTH0047-658 
treated syngeneic SMA-560-bearing mice. A-E. SMA-560 (5x103) glioma cells were 659 
injected stereotactically into the right hemisphere of VM/Dk mice. Five days after tumor 660 
inoculation, systemic treatment with C3_ISTH0047 (Ctrl) (20 mg/kg), ISTH1047 (10 661 




administered twice weekly. Brains from glioma-bearing mice were extracted for 663 
histological analyses from three pre-randomized animals per group when the first mouse 664 
developed clinical symptoms to detect CD45+ leukocyte (A), CD3+ T cell (B), CD8+ 665 
cytotoxic T cell (C), CD4+ T helper cell (D) or CD11b+ monocyte/microglia (E) populations. 666 
Results are expressed as means and SD (n=12), statistical analysis was performed with 667 
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